1. Escherichia coli LTB26 mutant enhances immune responses to rotavirus antigen VP8 in a mouse model.
- Author
-
Shi, Qinlin, Wang, Qiujuan, Shen, Yanxi, Chen, Sijing, Gan, Sijie, Lin, Tao, Song, Fangzhou, and Ma, Yongping
- Subjects
- *
B cell receptors , *ESCHERICHIA coli , *MAJOR histocompatibility complex , *ENZYME-linked immunosorbent assay , *IMMUNOLOGICAL adjuvants - Abstract
Adjuvant is a major supplementary component of vaccines to boost adaptive immune responses. To select an efficient adjuvant from the heat-labile toxin B subunit (LTB) of E. coli , four LTB mutants (numbered LTB26, LTB34, LTB57, and LTB85) were generated by multi-amino acid random replacement. Mice have been intranasally vaccinated with human rotavirus VP8 admixed. Among the four mutants, enzyme-linked immunosorbent assay (ELISA) revealed that LTB26 had enhanced mucosal immune adjuvanticity compared to LTB, showing significantly enhanced immune responses in both serum IgG and mucosal sIgA levels. The 3D modeling analysis suggested that the enhanced immune adjuvanticity of LTB26 might be due to the change of the first LTB α-helix to a β-sheet. The molecular mechanism was studied using transcriptomic and flow cytometric (FCM) analysis. The transcriptomic data demonstrated that LTB26 enhanced immune response by enhancing B cell receptor (BCR) and major histocompatibility complex (MHC) II+-related pathways. Furthermore, LTB26 promoted Th1 and Th2-type immune responses which were confirmed by detecting IFN-γ and IL-4 expression levels. Immunohistochemical analysis demonstrated that LTB26 enhanced both Th1 and Th2 type immunity. Therefore, LTB26 was a potent mucosal immune adjuvant meeting the requirement for use in human clinics in the future. • The adjuvant activity of LTB and its mutants are not as proportional to the GM-binding affinity as previously reported. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF